PDCD1 and cancer: Accordingly, anti-PD-1 therapies (e.g., nivolumab) are based on improving the anti-tumor immune response against cancer cells, principally by stimulating the infiltrating cytotoxic T lymphocytes (CD8+) in the tumor microenvironment5–7.